security

Document Security Systems Inc (NYSE: DSS) Subsidiary Impact BioMedical Inc. Announces Second U.S. Copyright Delivered for its Branded Equivir Composite – Tech Stock Observer


Document Security Systems Inc (NYSE: DSS) subsidiary Impact BioMedical Inc. announced that it has been issued copyright on June 15, 2021, from the U.S. Patent and Trademark Office for its branded composite Equivir. 

Second copyright issues to the company for Equivir

It is a follow-up to the discharge on April 6, 2021, for the grant of this copyright. The composite has exhibited happy pre-clinical moments that decrease the danger and harshness attributable to virus-related contagions, precisely Ebola and Rhinovirus.

This copyright is the second delivered to Impact BioMedical for Equivir; the first was delivered August 20, 2019, with rights focused on a technique of regulating the incidence of, plummeting the risk or harshness of, or handling influenza contagion.

“This is the second copyright for Equivir and enlarges Impact BioMedical’s intellectual properties in this expanse,” said Frank D. Heuszel, CEO of DSS. “We are looking for a third copyright for Equivir, with the expectation of increasing its latent in a diversity of antiviral requests and providing long-term worth.”

Equivir is supposed to purpose by obstructing a virus’s aptitude to contaminate and duplicate in host cells. In use much like a multivitamin, Equivir was strictly intended for simplicity of rapid convenience and placement. However, pre-clinical in-vitro achievement showed Equivir is hypothetically useful for epidemics and viral eruptions against SARS-COV2, Influenza, Ebola, Cholera, and Rhinovirus.

Drug applicant to help manage rare viral diseases

Ebola, also recognized as Ebola Virus Disease (EVD) or Ebola Hemorrhagic fever (EHF), is an uncommon but stark and often terminal illness in beings, predominantly in sub-Saharan Africa. Ebola has a demise rate of up to 90 percent, rendering to the World Health Organization. Rhinovirus is the most shared viral infectious agent in beings and is the leading cause of the common cold.

“Equivir is intended to address developing viral waves and epidemics. This latest copyright will support our investigation to determine Equivir as a deployable tactical defense for a broad variety of virus-related infections,” said Daryl Thompson, Impact BioLife’s Director of Scientific Initiatives.

Impact BioMedical states that it has a third Equivir copyright impending which contains entitlements focused on a technique of restraining the incidence of, plummeting the risk or harshness of, or handling other viral contagions. Impact BioMedical has also finished a research study that assessed the possible efficiency of Equivir in in-vitro studies constraining viral contagions comprising SARS-COV2.

Disclaimer: Our content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. We recommend that you consult a licensed financial advisor or conduct your own research before making any investment decisions.

TechStockObserver.com is not a broker/dealer, we are not an investment advisor, we have no access to non-public information about publicly traded companies, and this is not a place for the giving or receiving of financial advice, advice concerning investment decisions or tax or legal advice.

TechStockObserver.com does not accept liability for your use of the website. The website is provided on an “as is” and “as available” basis, without any representations, warranties or conditions of any kind.

Principals of TechStockObserver.com may own positions in the securities listed on the site and that we reserve the right to sell without notice at any time. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.




READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.